Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 16.50
Bid: 16.00
Ask: 17.00
Change: -1.00 (-5.71%)
Spread: 1.00 (6.25%)
Open: 14.50
High: 16.50
Low: 14.50
Prev. Close: 17.50
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Admission of the First Tranche Placing Shares

29 Apr 2024 07:00

RNS Number : 2850M
Renalytix PLC
29 April 2024
 

Renalytix plc

("Renalytix" or the "Company")

 

Admission of the First Tranche Placing Shares

 

LONDON and SALT LAKE CITY - 29 April 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) confirms that, further to the announcements made on 12 March 2024 and 15 March 2024, the First Resale Registration Statement is expected to become effective later today and accordingly an application has been made to London Stock Exchange plc for the admission to trading of the First Tranche Placing Shares. The First Tranche Placing Shares, being 19,986,031 shares, were issued on 14 March 2024 and will be admitted to trading on AIM on 30 April 2024 at 8am.

 

The First Tranche Placing Shares have been credited as fully paid and rank pari passu in all respects with the Company's existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid on or in respect of such shares after the date of issue.

 

Capitalised terms used but not defined in this announcement have the meanings given to them in the announcement dated 12 March 2024, unless the context provides otherwise.

 

For further information, please contact:

 

Renalytix plc

www.renalytix.com

James McCullough, CEO

Via Walbrook PR

 

Stifel (Nominated Adviser, Joint Broker)

Tel: 020 7710 7600

Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea

 

Harry Billen

 

 

Investec Bank plc (Joint Broker)

Tel: 020 7597 4000

Gary Clarence / Shalin Bhamra

 

Walbrook PR Limited

Paul McManus / Alice Woodings / Charlotte Edgar

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Mob: 07980 541 893 / 07407 804 654 / 07884 664 686

CapComm Partners

Peter DeNardo

Tel: 415-389-6400 or investors@renalytix.com

 

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

 

Disclosure requirements of the Takeover Code

Under Rule 8.3(a) of the City Code on Takeovers and Mergers ("Takeover Code"), any person who is interested in one per cent. or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified.

An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 p.m. (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 p.m. (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Takeover Code, any person who is, or becomes, interested in one per cent. or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 p.m. (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPPUMCCUPCGAQ
Date   Source Headline
17th Oct 20227:00 amRNSPresentations accepted at ASN Kidney Week
20th Sep 20227:50 amRNSDirectorate Change
12th Sep 20227:00 amRNSIssue of shares
8th Sep 20227:00 amRNSRenalytix to Present at H.C. Wainwright Conference
17th Aug 202212:00 pmRNSBusiness update
8th Aug 20227:00 amRNSPublication of clinical utility study in The AJMC
30th Jun 20227:00 amRNSRenalytix Reports Financial Results for Q3 of FY22
23rd Jun 20227:00 amRNSRenalytix to Report Financial Results for Q3
10th Jun 20227:00 amRNSMount Sinai clinical utility data
8th Jun 20227:00 amRNSRenalytix to Present at Growth Stock Conference
6th Jun 20227:00 amRNSData Presentations at ADA 82nd Scientific Sessions
6th Jun 20227:00 amRNSKidneyIntelX data shows ability to assess risk
29th Apr 20224:46 pmRNSTotal Voting Rights
22nd Apr 20227:00 amRNSGrant of Share Options
8th Apr 20227:00 amRNSSuccessful completion of $30.0m financing package
8th Apr 20227:00 amRNSIssue of shares
31st Mar 20227:05 amRNS$30.0 million financing package
31st Mar 20227:00 amRNSHalf-year Report
30th Mar 20227:00 amRNSTimothy Scannell appointed to the Board
29th Mar 20227:00 amRNSEnrollment Milestone for KidneyIntelX
25th Mar 20227:00 amRNSNotice of Results
9th Mar 20227:00 amRNSRenalytix Launches myIntelX
24th Feb 20227:00 amRNSPresentation of new clinical data for KidneyIntelX
22nd Feb 20227:01 amRNSRENX to Present at Cowen 42nd Annual Conference
22nd Feb 20227:00 amRNSTimothy Scannell to be appointed to board
27th Jan 20223:19 pmRNSGrant of Share Options
27th Jan 20227:00 amRNSConference attendance
11th Jan 20221:06 pmRNSPositive Study Results Published for KidneyIntelX
10th Jan 20227:00 amRNSPartnership with Singing River for KidneyIntelX
7th Jan 20227:00 amRNSAppointment of Jean M. Casner as CHRO
5th Jan 20227:00 amRNSRENX to present at 40th JP Morgan Healthcare Conf.
4th Jan 20227:00 amRNSJoint program with American Diabetes Association
17th Dec 20213:38 pmRNSResult of AGM
17th Dec 202111:26 amRNSDirector/PDMR Shareholding
13th Dec 20217:00 amRNSDirector/PDMR Shareholding
9th Dec 20217:00 amRNSDirector/PDMR Shareholding
8th Dec 20217:00 amRNSDirector/PDMR Shareholding
7th Dec 20217:00 amRNSRenalytix Reports Financial Results for Q1 of FY22
2nd Dec 20217:00 amRNSNotice of Q1 FY22 Results
19th Nov 20214:43 pmRNSPublication of Annual Report 2021 & Notice of AGM
10th Nov 20217:00 amRNSRenalytix Convenes Panel at VA Healthcare Summit
9th Nov 20217:00 amRNSPartnership with St. Joseph’s Health
1st Nov 202112:00 pmRNSIssue of shares and Total Voting Rights
21st Oct 20217:00 amRNSRenalytix Reports Full Year Fiscal 2021 Results
8th Oct 20217:00 amRNSRenalytix to Report Q4 and Full Year Results
7th Oct 20217:00 amRNSVA Health System roll-out & VP sales appointment
16th Sep 202112:17 pmRNSSecond Price Monitoring Extn
15th Sep 202111:06 amRNSSecond Price Monitoring Extn
15th Sep 202111:01 amRNSPrice Monitoring Extension
14th Sep 20216:15 pmRNSUpdate on MCIT Rule

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.